Notifications
Clear all
Topic starter
24/10/2022 7:31 am
Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD
https://doi.org/10.1021/acs.jafc.1c03105
Previous studies showed that Metformin is an SLC13A5 inhibitor, Gluconate is an SLC25A1 inhibitor and Hydroxycitrate is an ACLY inhibitor. A combination of SLC13A5, SLC25A1 and ACLY inhibitors may be necessary to adequately reduce citrate levels in the tumor environment.
Citrate transporter inhibitors: possible new anticancer agents
Combination of mitochondrial and plasma membrane citrate transporter inhibitors inhibits de novo lipogenesis pathway and triggers apoptosis
Daniel reacted